Bolt Biotherapeutics: Mixed Financial Results

Bolt Biotherapeutics reported a third-quarter loss of $7.1 million, or $3.72 per share, surpassing Wall Streets expectations of $5.07 per share. The company also generated $2.2 million in revenue. However, their stock value has significantly dropped from $12.84 a year ago to $4.69, indicating a challenging market performance.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.